Table of Contents
Introduction
Suvorexant is an oral hypnotic drug marketed under the brand name Belsomra. Pharmacologically, suvorexant is a dual orexin receptor antagonist, commonly called a DORA.
Insomnia is a sleep disorder characterized by difficulty falling asleep, difficulty staying asleep, or both. Unlike traditional sedative-hypnotic drugs that broadly depress the central nervous system through GABAergic mechanisms, suvorexant promotes sleep by reducing wake-promoting orexin signaling.
Orexins, also called hypocretins, are neuropeptides produced mainly in the lateral hypothalamus. The two main orexin peptides are orexin A and orexin B. They bind to orexin receptors OX1R and OX2R and help maintain wakefulness, arousal, alertness, and sleep-wake stability.
Suvorexant works by blocking orexin receptors. The official Belsomra label states that the mechanism of action of suvorexant in insomnia is presumed to be antagonism of orexin receptors. Blocking orexin A and orexin B binding to OX1R and OX2R is thought to suppress wake drive.
Belsomra is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. It is a Schedule IV controlled substance and is contraindicated in patients with narcolepsy.
For exam purposes, suvorexant should be remembered as a dual orexin receptor antagonist used for insomnia. Its key mechanism is suppression of wake drive by blocking OX1R and OX2R, not by directly activating GABA receptors like benzodiazepines or Z-drugs.
Mechanism of Action (Step-wise)
Step 1: Wakefulness is maintained by arousal systems
Normal wakefulness depends on several CNS arousal pathways, including orexin, histamine, norepinephrine, dopamine, serotonin, acetylcholine, and glutamate pathways. These systems help maintain alertness during the day and prevent unwanted transition into sleep.
Step 2: Orexin neurons are located mainly in the hypothalamus
Orexin-producing neurons are located mainly in the lateral hypothalamus and project widely throughout the brain. These neurons activate multiple wake-promoting centers and stabilize the sleep-wake cycle.
Step 3: Orexin A and orexin B promote wakefulness
Orexin A and orexin B are wake-promoting neuropeptides. They help maintain arousal, vigilance, motivation, feeding behavior, sympathetic tone, and stable transitions between wakefulness, non-REM sleep, and REM sleep.
Step 4: Orexins act through OX1R and OX2R receptors
Orexin A and orexin B act mainly through two G-protein-coupled receptors: OX1R and OX2R. OX1R and OX2R are expressed in several brain regions involved in arousal and sleep-wake control.
Step 5: Orexin signaling stabilizes wakefulness
During wakefulness, orexin signaling helps keep arousal centers active. This prevents sudden sleep attacks and maintains normal daytime alertness. Loss of orexin signaling is strongly associated with narcolepsy, which explains why orexin receptor blockade can produce narcolepsy-like adverse effects.
Step 6: Excess wake drive contributes to insomnia
In insomnia, patients may have difficulty initiating sleep, maintaining sleep, or returning to sleep after awakening. Increased arousal and persistent wake drive can contribute to difficulty sleeping.
Step 7: Suvorexant binds OX1R and OX2R
Suvorexant binds to both orexin receptors, OX1R and OX2R. The official label reports binding to OX1R and OX2R with high affinity, with Ki values of 0.55 nM and 0.35 nM respectively.
Step 8: Suvorexant blocks orexin receptor activation
By occupying orexin receptors, suvorexant prevents orexin A and orexin B from activating OX1R and OX2R. This reduces orexin-mediated stimulation of wake-promoting neural circuits.
Step 9: Wake-promoting signaling decreases
When orexin receptor signaling is blocked, downstream arousal pathways become less active. This decreases wake drive and makes it easier for sleep-promoting systems to dominate.
Step 10: Sleep onset improves
By reducing wake drive, suvorexant can help patients fall asleep more easily. This explains its use in insomnia with difficulty initiating sleep.
Step 11: Sleep maintenance improves
Orexin signaling also helps maintain wakefulness after nighttime awakenings. Blocking orexin receptors can reduce nighttime wakefulness and improve ability to stay asleep.
Step 12: Suvorexant does not directly activate GABA-A receptors
Suvorexant is not a benzodiazepine, barbiturate, or Z-drug. It does not primarily cause sleep by directly enhancing GABA-A receptor activity. Instead, it reduces wakefulness by antagonizing orexin receptors.
Step 13: REM-related phenomena may occur
Because orexin signaling helps stabilize sleep-wake and REM transitions, blocking orexin receptors may cause sleep paralysis, hypnagogic or hypnopompic hallucinations, and cataplexy-like symptoms in some patients. The label specifically warns about these effects.
Step 14: Daytime impairment may occur
If orexin blockade persists into the next day, patients may experience somnolence, impaired alertness, slowed reaction time, impaired driving, or increased fall risk. This is why adequate sleep time after dosing is important.
Step 15: Final therapeutic outcome
The final therapeutic outcome of suvorexant is improved sleep onset and/or sleep maintenance by suppressing orexin-mediated wake drive. It treats insomnia symptoms but does not cure underlying psychiatric, neurological, respiratory, or circadian causes of sleep disturbance.
Pharmacokinetics
Suvorexant is administered orally as Belsomra tablets. The recommended dose is 10 mg taken no more than once per night, within 30 minutes of going to bed, with at least 7 hours remaining before planned awakening. If 10 mg is tolerated but not effective, the dose may be increased. The maximum recommended dose is 20 mg once nightly.
Belsomra tablets are available as 5 mg, 10 mg, 15 mg, and 20 mg film-coated tablets. The lowest effective dose should be used to reduce next-day impairment and other dose-related adverse effects.
Suvorexant should not be taken with less than a full night of sleep remaining. Taking it late at night or without adequate time in bed increases the risk of next-day drowsiness, impaired driving, and reduced mental alertness.
Food can delay the onset of effect. A high-fat meal does not meaningfully change total exposure, but it delays the time to peak concentration by about 1.5 hours. Therefore, for faster sleep onset, taking suvorexant with or immediately after a meal may be less ideal.
Suvorexant reaches peak plasma concentration at a median time of about 2 hours under fasting conditions, with a range of 30 minutes to 6 hours. The mean absolute bioavailability of the 10 mg dose is approximately 82%.
Suvorexant is highly protein bound, more than 99%, mainly to albumin and alpha-1 acid glycoprotein. Its mean volume of distribution is approximately 49 L.
Suvorexant is metabolized mainly by CYP3A, with a minor contribution from CYP2C19. The major circulating drug-related entities are suvorexant and a hydroxy-suvorexant metabolite, which is not expected to be pharmacologically active.
The mean elimination half-life is approximately 12 hours. Steady state is achieved by about 3 days, and accumulation with once-daily dosing is approximately 1- to 2-fold.
Elimination occurs mainly through feces. After radiolabeled dosing, approximately 66% of the dose is recovered in feces and about 23% in urine.
Drug interactions are clinically important. Strong CYP3A inhibitors such as ketoconazole, itraconazole, clarithromycin, ritonavir, and similar agents are not recommended because they can increase suvorexant exposure. With moderate CYP3A inhibitors, the recommended suvorexant dose is 5 mg, generally not exceeding 10 mg. Strong CYP3A inducers such as rifampin, carbamazepine, and phenytoin can reduce suvorexant exposure and may reduce efficacy.
No dose adjustment is required in renal impairment. No dose adjustment is required in mild or moderate hepatic impairment, but Belsomra is not recommended in severe hepatic impairment.
Clinical Uses
Suvorexant is used for the treatment of insomnia in adults who have difficulty with sleep onset, sleep maintenance, or both. This means it may help patients who have trouble falling asleep, staying asleep, or returning to sleep after waking at night.
Suvorexant is especially important pharmacologically because it targets the wake-promoting orexin system rather than broadly depressing the CNS through GABA-A receptor modulation.
Suvorexant is not used for narcolepsy. In fact, Belsomra is contraindicated in patients with narcolepsy because blocking orexin signaling can worsen narcolepsy-like features.
Suvorexant is not an antidepressant, antipsychotic, benzodiazepine, Z-drug, melatonin receptor agonist, antihistamine, or barbiturate. It is a dual orexin receptor antagonist.
Suvorexant should not be used as a substitute for evaluating underlying causes of insomnia. The label notes that insomnia may be the presenting manifestation of a physical or psychiatric disorder, and failure of insomnia to improve after 7 to 10 days may indicate another condition that requires evaluation.
Suvorexant is not approved for pediatric patients. Safety and effectiveness in children have not been established.
Adverse Effects
The adverse effects of suvorexant are mainly related to CNS depression, persistent sleepiness, altered sleep-wake transitions, psychiatric effects, and drug interactions.
The most important warning is CNS depressant effect and daytime impairment. Belsomra can impair daytime wakefulness even when used as prescribed. Patients may experience somnolence, slowed reaction time, impaired alertness, and impaired driving. The risk increases with higher doses, use with CNS depressants, insufficient sleep time after dosing, and drugs that increase suvorexant blood levels.
Driving impairment is exam-relevant. The label states that driving ability was impaired in some individuals taking 20 mg, and patients taking 20 mg should be cautioned against next-day driving and other activities requiring full mental alertness. Lower doses may also impair driving in sensitive individuals.
Falls can occur, especially in elderly patients, because Belsomra can cause drowsiness and impaired coordination.
Suvorexant can worsen depression or suicidal ideation. In clinical studies, a dose-dependent increase in suicidal ideation was observed. Patients with depression, suicidal thoughts, or new behavioral symptoms should be evaluated carefully.
Complex sleep behaviors can occur. These include sleep-walking, sleep-driving, preparing and eating food, making phone calls, or having sex while not fully awake. Patients usually do not remember these events. Belsomra should be discontinued immediately if complex sleep behavior occurs.
Sleep paralysis, hypnagogic hallucinations, hypnopompic hallucinations, and cataplexy-like symptoms may occur. These effects are mechanistically related to orexin receptor antagonism and abnormal sleep-wake transition phenomena.
Respiratory caution is important. The effect of Belsomra on respiratory function should be considered in patients with compromised respiratory function. It has not been studied in patients with severe obstructive sleep apnea or severe COPD.
The most common adverse reaction in clinical trials was somnolence. In patients treated with 15 mg or 20 mg, somnolence occurred in 7% of Belsomra-treated patients compared with 3% of placebo-treated patients. Other adverse reactions included headache, dizziness, abnormal dreams, diarrhea, dry mouth, upper respiratory tract infection, and cough.
Alcohol should not be used with suvorexant because additive psychomotor impairment can occur. Combining suvorexant with benzodiazepines, opioids, tricyclic antidepressants, sedating antihistamines, antipsychotics, or other CNS depressants can increase sedation and impairment risk.
Suvorexant is a Schedule IV controlled substance. Abuse can increase the risk of somnolence, daytime sleepiness, impaired reaction time, and impaired driving. Patients with a history of substance misuse should be assessed carefully.
Comparative Analysis
Suvorexant is commonly compared with lemborexant, daridorexant, zolpidem, zaleplon, eszopiclone, benzodiazepines, ramelteon, melatonin, doxepin, trazodone, and sedating antihistamines.
Compared with lemborexant, suvorexant belongs to the same broad class of dual orexin receptor antagonists. Both block OX1R and OX2R and reduce wake drive. They differ in pharmacokinetics, dosing, approved formulations, adverse-effect profile, and clinical response.
Compared with daridorexant, suvorexant also blocks dual orexin receptors. Daridorexant is another DORA used for insomnia. Both reduce wakefulness by orexin antagonism, but they differ in half-life, dosing, next-day effect considerations, and clinical trial data.
Compared with zolpidem, suvorexant has a different mechanism. Zolpidem is a Z-drug that enhances GABA-A receptor activity through the benzodiazepine receptor site, especially involving alpha-1 subunits. Suvorexant does not primarily enhance GABA; it blocks orexin-mediated wake drive.
Compared with benzodiazepines such as temazepam, lorazepam, or diazepam, suvorexant is less broadly GABAergic. Benzodiazepines enhance GABA-A receptor activity and can cause sedation, muscle relaxation, anxiolysis, anticonvulsant effects, tolerance, dependence, and withdrawal. Suvorexant targets orexin receptors and has a different adverse-effect profile.
Compared with ramelteon, suvorexant acts on the orexin system, while ramelteon is a melatonin MT1/MT2 receptor agonist. Ramelteon is mainly used for sleep-onset insomnia and is not a controlled substance, while suvorexant is Schedule IV.
Compared with low-dose doxepin, suvorexant has a different target. Low-dose doxepin helps sleep maintenance mainly through histamine H1 receptor antagonism. Suvorexant improves sleep by reducing orexin-driven wakefulness.
Compared with sedating antihistamines such as diphenhydramine or doxylamine, suvorexant is more specific to the sleep-wake system. Antihistamines block H1 receptors and often cause anticholinergic effects such as dry mouth, constipation, urinary retention, confusion, and next-day sedation.
Compared with trazodone, suvorexant is an approved insomnia medication with orexin receptor antagonism. Trazodone is an antidepressant often used off-label for insomnia and acts through serotonergic, histaminergic, and adrenergic mechanisms.
Compared with melatonin, suvorexant does not primarily shift circadian rhythm. Melatonin supports circadian signaling through melatonin receptors, while suvorexant suppresses wake drive through orexin receptor blockade.
MCQs
- Suvorexant is marketed under which brand name?
a) Ambien
b) Belsomra
c) Lunesta
d) Rozerem
Answer: b) Belsomra
- Suvorexant belongs to which pharmacological class?
a) Dual orexin receptor antagonist
b) Benzodiazepine receptor agonist
c) Melatonin receptor agonist
d) Histamine H1 antagonist
Answer: a) Dual orexin receptor antagonist
- The main receptors blocked by suvorexant are:
a) GABA-A alpha-1 receptors
b) OX1R and OX2R
c) MT1 and MT2 receptors
d) Dopamine D2 receptors
Answer: b) OX1R and OX2R
- Orexin A and orexin B normally promote:
a) Wakefulness and arousal
b) Platelet aggregation
c) Gastric acid secretion only
d) Insulin release only
Answer: a) Wakefulness and arousal
- Suvorexant improves insomnia mainly by:
a) Suppressing wake drive
b) Stimulating dopamine release
c) Blocking bacterial ribosomes
d) Activating beta-1 receptors
Answer: a) Suppressing wake drive
- Suvorexant is indicated for insomnia characterized by:
a) Sleep onset and/or sleep maintenance difficulty
b) Acute psychosis
c) Narcolepsy with cataplexy
d) Epilepsy
Answer: a) Sleep onset and/or sleep maintenance difficulty
- Belsomra is contraindicated in patients with:
a) Narcolepsy
b) Hypertension only
c) Migraine
d) Hypothyroidism
Answer: a) Narcolepsy
- The usual recommended starting dose of Belsomra is:
a) 10 mg once nightly
b) 100 mg twice daily
c) 5 mg every morning
d) 300 mg intravenously monthly
Answer: a) 10 mg once nightly
- The maximum recommended dose of Belsomra is:
a) 20 mg once nightly
b) 80 mg once nightly
c) 150 mg twice daily
d) 5 mg once weekly
Answer: a) 20 mg once nightly
- Belsomra should be taken when the patient has at least:
a) 7 hours before planned awakening
b) 1 hour before planned awakening
c) 24 hours before planned awakening
d) 30 minutes before daytime work
Answer: a) 7 hours before planned awakening
- Which enzyme mainly metabolizes suvorexant?
a) CYP3A
b) Acetylcholinesterase
c) Monoamine oxidase-B
d) DPP-4
Answer: a) CYP3A
- Strong CYP3A inhibitors may:
a) Increase suvorexant exposure and adverse effects
b) Completely eliminate sedation risk
c) Convert suvorexant into zolpidem
d) Prevent insomnia permanently
Answer: a) Increase suvorexant exposure and adverse effects
- Which adverse effect is most common with Belsomra in clinical trials?
a) Somnolence
b) Severe hypoglycemia
c) Ototoxicity
d) Gingival hyperplasia
Answer: a) Somnolence
- Which sleep-related adverse effect may occur with suvorexant?
a) Sleep paralysis and hypnagogic/hypnopompic hallucinations
b) Permanent REM sleep elimination
c) Forced daytime wakefulness
d) Complete prevention of dreams
Answer: a) Sleep paralysis and hypnagogic/hypnopompic hallucinations
- Which statement best describes suvorexant?
a) It blocks OX1R and OX2R, reducing orexin-mediated wake drive in insomnia
b) It directly activates GABA-A receptors like benzodiazepines
c) It stimulates melatonin receptors only
d) It inhibits acetylcholinesterase to improve cognition
Answer: a) It blocks OX1R and OX2R, reducing orexin-mediated wake drive in insomnia
FAQs
What is the mechanism of action of suvorexant?
Suvorexant blocks orexin receptors OX1R and OX2R. By preventing orexin A and orexin B from activating these receptors, it suppresses wake drive and helps improve sleep onset and sleep maintenance.
What is the brand name of suvorexant?
The brand name of suvorexant is Belsomra.
What is suvorexant used for?
Suvorexant is used for insomnia in adults who have difficulty falling asleep, staying asleep, or both.
Is suvorexant a benzodiazepine?
No. Suvorexant is not a benzodiazepine. It is a dual orexin receptor antagonist. Benzodiazepines enhance GABA-A receptor activity, while suvorexant blocks orexin-mediated wakefulness.
Why is suvorexant contraindicated in narcolepsy?
Narcolepsy is associated with impaired orexin signaling. Since suvorexant blocks orexin receptors, it can worsen narcolepsy-like symptoms and is contraindicated in patients with narcolepsy.
Can suvorexant cause next-day sleepiness?
Yes. Suvorexant can cause next-day drowsiness, impaired alertness, slowed reaction time, impaired driving, and fall risk, especially at higher doses or when taken without enough time for sleep.
Why should alcohol be avoided with suvorexant?
Alcohol can add to the CNS depressant and psychomotor-impairing effects of suvorexant. This increases the risk of sedation, impaired coordination, abnormal behavior, and accidents.
What are common adverse effects of suvorexant?
Common adverse effects include somnolence, headache, dizziness, abnormal dreams, dry mouth, diarrhea, upper respiratory tract infection, and cough.
References
Goodman & Gilman’s The Pharmacological Basis of Therapeutics
Katzung Basic & Clinical Pharmacology
K.D. Tripathi Essentials of Medical Pharmacology
Harrison’s Principles of Internal Medicine
